Namrata Saroj - Jun 11, 2025 Form 3 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Business Officer
Signature
/s/ Todd Anderman, Attorney-in-Fact for Namrata Saroj
Stock symbol
OCUL
Transactions as of
Jun 11, 2025
Transactions value $
$0
Form type
3
Date filed
6/23/2025, 09:09 PM
Next filing
Nov 7, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Saroj Namrata Chief Business Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD /s/ Todd Anderman, Attorney-in-Fact for Namrata Saroj 2025-06-23 0002073624

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OCUL Common Stock 200K Jun 11, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCUL Stock Option (Right to Buy) Jun 11, 2025 Common Stock 50K $9.95 Direct F2
holding OCUL Stock Option (Right to Buy) Jun 11, 2025 Common Stock 100K $9.95 Direct F3
holding OCUL Stock Option (Right to Buy) Jun 11, 2025 Common Stock 316K $10.27 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 200,000 restricted stock units ("RSUs") remaining unvested pursuant to an award of 200,000 RSUs granted under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation") on November 4, 2024. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the reporting person's first date of employment and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2 This option is fully vested and exercisable.
F3 This option was granted on February 28, 2024 and vests over four years, with 1/4 of the shares underlying the option having vested on February 28, 2025 and 1/48 of the shares vesting monthly thereafter.
F4 This option was granted on November 4, 2024 and vests over four years, with 1/4 of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and 1/48 of the shares vesting monthly thereafter.

Remarks:

Exhibit 24 - Power of Attorney